Dr. Tara M. Graff, DO
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Lake Erie College of Osteopathic Medicine, Erie (2009)
- Years since graduation
- 17
- In the NPI registry since
- 2009
- Medicare patients seen, 2024
- 1,013
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2009Medical school: Lake Erie College of Osteopathic Medicine, Erie
- 2009Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
IA license DO-04560 -
Hematology & Oncology Physician
IA license 4560
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Iowa Hospital & Clinics Iowa City, IA
- Mercyone Des Moines Medical Center Des Moines, IA
- Unitypoint Health - Des Moines Iowa Methodist Medi Des Moines, IA
- Mercyone Centerville Medical Center Centerville, IA
- Davis County Hospital Bloomfield, IA
Medical groups
- State University of Iowa (1,897 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,013
- Services billed
- 208,423
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram | 17,280 | 14 |
| Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 15,300 | 21 |
| Injection, pembrolizumab, 1 mg | 13,400 | 27 |
| Injection, denosumab, 1 mg | 13,260 | 84 |
| Injection, aprepitant, 1 mg | 6,630 | 27 |
| Injection, iron sucrose, 1 mg | 5,100 | 16 |
| Injection, paclitaxel, 1 mg | 4,367 | 11 |
| Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 3,230 | 17 |
| Injection, docetaxel, 1 mg | 3,051 | 11 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,820 | 74 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Acyclovir Other prescribers in Clive, IA | 320 |
| Anastrozole Other prescribers in Clive, IA | 301 |
| Letrozole Other prescribers in Clive, IA | 210 |
| Calquence (acalabrutinib maleate) | 138 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Clive, IA | 98 |
| Dexamethasone Other prescribers in Clive, IA | 84 |
| Lenalidomide | 79 |
| Tamoxifen Citrate Other prescribers in Clive, IA | 75 |
| Eliquis (apixaban) Other prescribers in Clive, IA | 70 |
| Potassium Chloride Other prescribers in Clive, IA | 64 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 17 companies reported 142 payments worth $138,236 in total to this clinician.
| AbbVie Inc. | $37,272 |
|---|---|
| Genmab U.S., Inc. | $19,761 |
| AstraZeneca Pharmaceuticals LP | $18,507 |
| Incyte Corporation | $14,510 |
| Genentech USA, Inc. | $11,975 |
| Janssen Research & Development, LLC | $10,500 |
| Beone Medicines USA, Inc. | $10,162 |
| Lilly USA, LLC | $6,696 |
| Consulting Fee | $97,914 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $30,953 |
| Food and Beverage | $4,963 |
| Travel and Lodging | $4,396 |
| Education | $9.65 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Research & Development, LLC May 2, 2025 | Consulting Fee | $10,500 |
| Genentech USA, Inc. Aug 20, 2025 | Consulting Fee Lunsumio; Columvi; Polivy · BioOncology | $5,872 |
| AbbVie Inc. Oct 1, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $5,600 |
| Genmab U.S., Inc. Sep 11, 2025 | Compensation for services other than consulting (speaking, faculty) Epkinly · Oncology | $4,900 |
| AbbVie Inc. Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) EPKINLY · ONCOLOGY | $4,900 |
| AbbVie Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) EPKINLY · ONCOLOGY | $4,900 |
| Genentech USA, Inc. Aug 21, 2025 | Consulting Fee Lunsumio; Columvi; Polivy · BioOncology | $4,209 |
| AstraZeneca Pharmaceuticals LP Feb 20, 2025 | Consulting Fee CALQUENCE · Oncology | $4,100 |
| Genmab U.S., Inc. Mar 13, 2025 | Consulting Fee Epkinly · Oncology | $3,900 |
| Genmab U.S., Inc. Jul 11, 2025 | Consulting Fee Epkinly · Oncology · in-kind | $3,900 |
All 74 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Dec 23, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to ORLANDO, FL · in-kind | $63.29 |
| AbbVie Inc. Dec 19, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $3,300 |
| AbbVie Inc. Dec 19, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $2,283 |
| Lilly USA, LLC Dec 18, 2025 | Compensation for services other than consulting (speaking, faculty) JAYPIRCA · Oncology Company’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $1,875 |
| AstraZeneca Pharmaceuticals LP Dec 17, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $2,870 |
| AstraZeneca Pharmaceuticals LP Dec 15, 2025 | Consulting Fee | $3,280 |
| Genmab U.S., Inc. Dec 15, 2025 | Consulting Fee Epkinly · Oncology · in-kind | $48.00 |
| AstraZeneca Pharmaceuticals LP Dec 14, 2025 | Consulting Fee | $820 |
| AbbVie Inc. Dec 9, 2025 | Education VENCLEXTA · ONCOLOGY · in-kind | $9.65 |
| Beone Medicines USA, Inc. Dec 2, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $1,950 |
| AstraZeneca Pharmaceuticals LP Nov 19, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $2,460 |
| Incyte Corporation Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $2,055 |
| Beone Medicines USA, Inc. Nov 19, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $975 |
| Genmab U.S., Inc. Nov 19, 2025 | Travel and Lodging Epkinly · Oncology · travel to Rosemont, IL · in-kind | $250 |
| Genmab U.S., Inc. Nov 19, 2025 | Travel and Lodging Epkinly · Oncology · travel to Rosemont, IL · in-kind | $171 |
| Genmab U.S., Inc. Nov 18, 2025 | Travel and Lodging Epkinly · Oncology · travel to Rosemont, IL · in-kind | $240 |
| Lilly USA, LLC Nov 14, 2025 | Consulting Fee JAYPIRCA · Oncology | $938 |
| E.r. Squibb & Sons, L.l.c. Nov 5, 2025 | Consulting Fee | $533 |
| AbbVie Inc. Oct 31, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $3,500 |
| E.r. Squibb & Sons, L.l.c. Oct 28, 2025 | Consulting Fee | $2,840 |
| AbbVie Inc. Oct 23, 2025 | Compensation for services other than consulting (speaking, faculty) EPKINLY · ONCOLOGY | $4,900 |
| E.r. Squibb & Sons, L.l.c. Oct 16, 2025 | Consulting Fee | $533 |
| AbbVie Inc. Oct 9, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $350 |
| AbbVie Inc. Oct 8, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to BETTENDORF, IA · in-kind | $258 |
| AbbVie Inc. Oct 7, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to CHICAGO, IL · in-kind | $294 |
| AbbVie Inc. Oct 7, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to CHICAGO, IL · in-kind | $48.00 |
| Genmab U.S., Inc. Oct 6, 2025 | Travel and Lodging Epkinly · Oncology · travel to Rosemont, IL · in-kind | $457 |
| AbbVie Inc. Oct 1, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $5,600 |
| Incyte Corporation Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $1,370 |
| AbbVie Inc. Sep 23, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $350 |
| Incyte Corporation Sep 18, 2025 | Consulting Fee Monjuvi · Oncology | $2,055 |
| Genmab U.S., Inc. Sep 11, 2025 | Compensation for services other than consulting (speaking, faculty) Epkinly · Oncology | $4,900 |
| Genmab U.S., Inc. Sep 4, 2025 | Travel and Lodging Epkinly · Oncology · travel to Cypress, TX | $563 |
| Genmab U.S., Inc. Sep 4, 2025 | Travel and Lodging Epkinly · Oncology · travel to Cypress, TX | $294 |
| Genmab U.S., Inc. Sep 4, 2025 | Travel and Lodging Epkinly · Oncology · travel to Des Moines, IA | $48.00 |
| Incyte Corporation Aug 26, 2025 | Consulting Fee Monjuvi · Oncology | $3,768 |
| Genentech USA, Inc. Aug 21, 2025 | Consulting Fee Lunsumio; Columvi; Polivy · BioOncology | $4,209 |
| Genentech USA, Inc. Aug 20, 2025 | Consulting Fee Lunsumio; Columvi; Polivy · BioOncology | $5,872 |
| Genentech USA, Inc. Aug 20, 2025 | Travel and Lodging Lunsumio; Columvi; Polivy · BioOncology · travel to San Francisco, CA · in-kind | $522 |
| Genentech USA, Inc. Aug 20, 2025 | Travel and Lodging Lunsumio; Columvi; Polivy · BioOncology · travel to San Francisco, CA · in-kind | $474 |
| Genentech USA, Inc. Aug 20, 2025 | Travel and Lodging Lunsumio; Columvi; Polivy · BioOncology · travel to San Francisco, CA · in-kind | $88.79 |
| Beone Medicines USA, Inc. Aug 11, 2025 | Consulting Fee BRUKINSA · Oncology | $3,600 |
| Incyte Corporation Aug 11, 2025 | Consulting Fee MONJUVI · Oncology | $3,083 |
| Genmab U.S., Inc. Aug 11, 2025 | Consulting Fee Epkinly · Oncology | $650 |
| AstraZeneca UK Limited Aug 5, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $2,460 |
| Incyte Corporation Jul 31, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $1,028 |
| Pfizer Inc. Jul 25, 2025 | Compensation for services other than consulting (speaking, faculty) ADCETRIS · ONCOLOGY | $360 |
| Genmab U.S., Inc. Jul 11, 2025 | Consulting Fee Epkinly · Oncology · in-kind | $3,900 |
| AbbVie Inc. Jul 11, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $700 |
| AbbVie Inc. Jun 13, 2025 | Consulting Fee VENCLEXTA · ONCOLOGY | $700 |
| Incyte Corporation May 30, 2025 | Compensation for services other than consulting (speaking, faculty) Monjuvi · Oncology | $343 |
| Incyte Corporation May 29, 2025 | Consulting Fee Monjuvi · Oncology | $685 |
| Genmab U.S., Inc. May 23, 2025 | Compensation for services other than consulting (speaking, faculty) Epkinly · Oncology | $600 |
| AbbVie Inc. May 16, 2025 | Compensation for services other than consulting (speaking, faculty) EPKINLY · ONCOLOGY | $2,100 |
| Genmab U.S., Inc. May 15, 2025 | Compensation for services other than consulting (speaking, faculty) Epkinly · Oncology | $2,100 |
| Janssen Research & Development, LLC May 2, 2025 | Consulting Fee | $10,500 |
| AbbVie Inc. Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) EPKINLY · ONCOLOGY | $4,900 |
| Beone Medicines USA, Inc. Apr 5, 2025 | Consulting Fee BRUKINSA · Oncology | $1,950 |
| AbbVie Inc. Apr 4, 2025 | Consulting Fee | $3,500 |
| AstraZeneca UK Limited Apr 3, 2025 | Consulting Fee | $820 |
| Beone Medicines USA, Inc. Mar 21, 2025 | Compensation for services other than consulting (speaking, faculty) BRUKINSA · Oncology | $1,138 |
| AstraZeneca Pharmaceuticals LP Mar 20, 2025 | Consulting Fee CALQUENCE · Oncology | $1,640 |
| Genmab U.S., Inc. Mar 13, 2025 | Consulting Fee Epkinly · Oncology | $3,900 |
| AbbVie Inc. Mar 7, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to INDIANAPOLIS, IN · in-kind | $80.00 |
| AstraZeneca Pharmaceuticals LP Feb 20, 2025 | Consulting Fee CALQUENCE · Oncology | $4,100 |
| Genmab U.S., Inc. Feb 12, 2025 | Travel and Lodging Epkinly · Oncology · travel to Fort Lauderdale, FL | $407 |
| Genmab U.S., Inc. Feb 12, 2025 | Travel and Lodging Epkinly · Oncology · travel to Fort Lauderdale, FL | $60.00 |
| Genmab U.S., Inc. Feb 12, 2025 | Travel and Lodging Epkinly · Oncology · travel to Fort Lauderdale, FL | $28.28 |
| Lilly USA, LLC Jan 27, 2025 | Consulting Fee JAYPIRCA · Oncology | $3,750 |
| AbbVie Inc. Jan 23, 2025 | Consulting Fee EPKINLY · ONCOLOGY | $350 |
| AbbVie Inc. Jan 13, 2025 | Consulting Fee | $3,150 |
| AbbVie Inc. Jan 8, 2025 | Travel and Lodging EPKINLY · ONCOLOGY · travel to DES MOINES, IA · in-kind | $50.00 |
| Pfizer Inc. Jan 7, 2025 | Compensation for services other than consulting (speaking, faculty) | $360 |
| AstraZeneca Pharmaceuticals LP Jan 1, 2025 | Consulting Fee CALQUENCE · Oncology | $2,870 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 28 industry-funded studies in 2025, from 11 companies. The companies reported $1,210,322 in research payments for these studies, mostly to the institutions running them.
- A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase MK-3475A in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma rrcH…
Merck Sharp & Dohme LLC - Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
Beigene, Ltd. · Active, not recruiting · NCT06073821 - Venetoclax In CLL Patients on BTKi Therapy to Optimize dept of Response for time off therapy
Genentech, Inc. - A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
Beigene, Ltd. · Active, not recruiting · NCT05100862 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
AbbVie Inc. · Active, not recruiting · NCT06191744 - A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who hav…
Janssen Research & Development, LLC - A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who hav…
Janssen Research & Development, LLC - A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple …
Janssen Research & Development, LLC - M20-621 - A Phase 3 Multicenter Randomized Open-Label Trial to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP compared to R-CHOP in Subjects with High-Risk Diffuse Large B-Cell Lymphoma
AbbVie Inc. - M22-003 - Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated …
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.